X4 Pharmaceuticals (XFOR) Change in Accured Expenses (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Change in Accured Expenses for 10 consecutive years, with -$2.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses fell 1391.19% year-over-year to -$2.9 million; the trailing twelve-month figure through Jun 2026 stood at $1.0 million (up 123.93% YoY), and the FY2025 full-year result was -$2.0 million, down 128.25% from the prior year.
• Change in Accured Expenses retreated to -$2.9 million in Q2 2026 per XFOR's latest filing, from -$1.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.5 million in Q2 2023 and bottomed at -$7.8 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $337500.0 across 5 years, with a median of $640500.0 in 2022.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses soared 2540.3% in 2022, then plunged 1391.19% in 2026.
• Over 5 years, Change in Accured Expenses stood at $2.5 million in 2022, then slumped by 261.85% to -$4.0 million in 2023, then soared by 182.54% to $3.3 million in 2024, then plunged by 35.12% to $2.2 million in 2025, then tumbled by 235.38% to -$2.9 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$2.9 million, -$1.5 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.